Analyzing Bavarian Nordic (OTCMKTS:BVNRY) and X4 Pharmaceuticals (NASDAQ:XFOR)

Bavarian Nordic (OTCMKTS:BVNRY) and X4 Pharmaceuticals (NASDAQ:XFOR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Bavarian Nordic and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bavarian Nordic	19.74%	9.32%	8.14%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

Earnings & Valuation

This table compares Bavarian Nordic and X4 Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bavarian Nordic	$945.43 million	2.29	$208.23 million	$0.76	11.96
X4 Pharmaceuticals	$35.11 million	12.21	-$79.20 million	($4.54)	-1.00

Bavarian Nordic has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Bavarian Nordic, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Bavarian Nordic and X4 Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bavarian Nordic	0	0	0	0	0.00
X4 Pharmaceuticals	1	1	5	0	2.57

X4 Pharmaceuticals has a consensus price target of $9.70, suggesting a potential upside of 113.42%. Given X4 Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Bavarian Nordic.

Risk & Volatility

Bavarian Nordic has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Summary

Bavarian Nordic beats X4 Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.